Novan, Inc. (NOVN)
Novan, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Durham, CA, US. The stock last traded at $0.09, down 24.84% on the session, giving a market capitalisation of $2.6M. On trailing twelve-month figures it carries a trailing P/E of -0.11, a net margin of -82.9%. Its beta of -0.04 implies it has historically moved less than the broad market.
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Novan, Inc. is most often compared with the following Healthcare names: